4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc. insiders are currently net buyers of FDMT stock, showing neutral sentiment over the past 90 days. Executives have purchased $51.1M while selling $24.2M, resulting in a positive net flow of $26.8M. This buying activity represents 68% of total transaction volume.

4D Molecular Therapeutics Inc. has 20 active insiders who have filed SEC Form 4 transactions in the past 90 days. David C. Ott (Executive) leads with 3 transactions totaling $25.3M. Rose Sharon Shabet (Executive) follows with 1 transactions worth $13.6M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. 4D Molecular Therapeutics Inc.'s current score of 68/100 indicates neutral insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $51.1M in purchases versus $24.2M in sales.

The most recent insider transaction occurred on Sep 1, 2026, when Bizily Scott (Chief Legal Officer) disposed of 584 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, FDMT insider trading sentiment is currently neutral with an Alignment Score of 68/100. The net insider flow of $26.8M reflects accumulation, with 68% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like 4D Molecular Therapeutics Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At FDMT, we track all Form 4 filings—currently showing 192 transactions from 20 insiders over 90 days.

A 10b5-1 plan allows 4D Molecular Therapeutics Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At FDMT, approximately 28% of recent transactions are 10b5-1 trades. The remaining 72% are discretionary trades, which may carry more informational value.

You can monitor 4D Molecular Therapeutics Inc. (FDMT) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 20 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. 4D Molecular Therapeutics Inc.'s current score of 68/100 indicates moderately bullish sentiment suggesting insider confidence. This is calculated from $51.1M in purchases versus $24.2M in sales over 90 days, resulting in a net flow of $26.8M.

SEC Form 4 filings are mandatory reports that 4D Molecular Therapeutics Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At FDMT, the most common type is "M" with 23 occurrences. The most recent Form 4 was filed on Sep 1, 2026 by Bizily Scott.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At 4D Molecular Therapeutics Inc., approximately 28% of recent transactions are executed under 10b5-1 plans, while 72% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.